Treatment Approach for Substance Use Disorder

Core Treatment Framework

• The American Medical Association recommends implementing combined pharmacotherapy plus cognitive behavioral therapy (CBT) or another evidence-based behavioral intervention for individuals with substance use disorder, while actively incorporating family members into treatment through couples/family therapy and mutual help groups 1
• Pharmacotherapy selection depends on the specific substance and presence of liver disease, with options including naltrexone, acamprosate, buprenorphine, or methadone for opioids 2
• Evidence-based behavioral therapy should be CBT, motivational enhancement therapy, contingency management, or relapse prevention—all have demonstrated effectiveness 2
• Combined treatment shows superior outcomes compared to usual care plus pharmacotherapy alone, making this the standard of care 1

Addressing Relational Dynamics

• Family members should engage with appropriate mutual help groups (such as Al-Anon) to address their own responses to the substance use disorder 3
• Failing to address family dynamics and social support systems negatively impacts treatment outcomes, making this a critical component rather than an optional add-on 3

Specific Pharmacotherapy Selection

For Alcohol Use Disorder:

• Naltrexone 50mg daily is recommended for patients without liver disease 3
• Acamprosate 666mg three times daily is recommended for patients with liver disease (no hepatotoxicity risk) 3
• Avoid naltrexone in alcoholic liver disease due to hepatotoxicity risk 3

For Opioid Use Disorder:

• Buprenorphine, methadone, or naltrexone are evidence-based options 2

For Stimulant Use Disorder:

• No pharmacotherapy can be recommended for cocaine or methamphetamine dependence in primary care 4
• Behavioral therapies alone have demonstrated effectiveness for stimulant dependence 4

Behavioral Intervention Specifics

• CBT provides training in behavioral self-control skills to achieve and maintain abstinence 3
• Motivational interviewing is particularly effective for patients ambivalent about cessation 3
• Brief interventions using the FRAMES model (Feedback, Responsibility, Advice, Menu of options, Empathy, Self-efficacy) in a single 5-30 minute session are effective for hazardous drinkers 3
• Use motivational rather than confrontational communication style throughout screening, counseling, and treatment 5

Treatment Duration and Monitoring

• Optimal pharmacotherapy duration is typically 3-6 months, with premature discontinuation reducing effectiveness 3
• Acamprosate should be initiated 3-7 days after last alcohol consumption and after withdrawal symptoms resolve 3
• Regular follow-up and reevaluation are essential for patients with substance abuse (not just dependence) 5

Common Pitfalls in Relational Contexts

• Relying solely on pharmacotherapy without behavioral interventions significantly reduces treatment effectiveness and fails to address the interpersonal dynamics driving the pursuer-withdrawer pattern 3
• Treating the individual in isolation without engaging family members misses a critical component of recovery, particularly when relational patterns contribute to substance use 3
• Using confrontational rather than motivational communication can reinforce the withdrawer position and worsen treatment engagement 5

Comorbidity Considerations

• Screen for anxiety disorders, depression, bipolar disorder, PTSD, and personality disorders, which are more common in patients with substance use disorders 4
• Intimate partner violence is common in patients with substance use disorders and requires specific assessment 5

Mutual Help Integration

• Actively encourage engagement with Alcoholics Anonymous, Narcotics Anonymous, or SMART Recovery as these are highly effective and should be routinely recommended 3
• Peer-led groups support all stages of recovery and are free and available in most communities 4

Evidence‑Based Management of Methamphetamine Use Disorder

First‑Line Behavioral Interventions

• Contingency management (CM) is the most efficacious treatment for stimulant use disorders, including methamphetamine, and is supported by AIa‑level evidence (the highest rating) from the International Antiviral Society‑USA Panel (2025). 6
• Combining CM with cognitive‑behavioral therapy (CBT) yields superior outcomes compared with either CM or CBT alone. The JAMA Network Open guideline panel reported greater abstinence rates when the two interventions are integrated. 7

Pharmacotherapy Guidance

• No medications are FDA‑approved for methamphetamine use disorder; the JAMA guideline panel (2025) explicitly states that pharmacologic treatment cannot be recommended in primary‑care settings. 6
• Pharmacologic agents may be considered only in limited, unspecified situations; routine use is not endorsed by the JAMA guideline panel. 6

Implementation Steps

Initiate Contingency Management

• Establish a system that provides financial incentives (e.g., cash or gift cards) contingent on twice‑weekly negative urine drug screens; this is the sole intervention with AIa‑level evidence for methamphetamine use disorder. 6

Add Cognitive‑Behavioral Therapy

• Integrate CBT with CM (or with any pharmacotherapy when used) to achieve greater benefit than usual care alone across substance‑use disorders. 7

Integrate Support Services

• Offer peer‑support staff, telehealth options, extended clinic hours, mobile units, and walk‑in availability to enhance engagement. 6
• Provide harm‑reduction resources such as naloxone distribution, safe‑use education, and fentanyl test strips alongside CM. 6

Clinical Pitfalls to Avoid

• Do not rely on pharmacotherapy alone for methamphetamine use disorder; behavioral interventions remain the primary evidence‑based approach. 6
• Do not prescribe off‑label medications without concurrent CM and CBT, as the evidence for pharmacotherapy alone is insufficient. 6
• Do not delay treatment initiation while awaiting pharmacologic options; CM and CBT are immediately available and evidence‑based. 6

Special Populations & Integrated Care

• For patients with HIV or at risk for HIV, integrate substance‑use treatment with HIV prevention or treatment services. 6
• Offer pre‑exposure prophylaxis (PrEP), oral or injectable, to reduce sexual HIV acquisition risk in individuals using methamphetamine. 6

Monitoring

• Conduct regular urine drug screening to both monitor abstinence and trigger contingency‑management incentives. 6